Additionally, the 36-month beta value for NUVB is 1.47. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NUVB is 229.10M and currently, short sellers hold a 6.72% ratio of that float. The average trading volume of NUVB on December 26, 2024 was 2.20M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NUVB) stock’s latest price update
The stock of Nuvation Bio Inc (NYSE: NUVB) has increased by 5.62 when compared to last closing price of 2.67. Despite this, the company has experienced a 0.36% gain in its stock price over the last five trading sessions. businesswire.com reported 2024-12-23 that NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that the U.S. FDA has accepted the company’s NDA for taletrectinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of advanced ROS1+ NSCLC (line agnostic). The U.S. FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2.
NUVB’s Market Performance
Nuvation Bio Inc (NUVB) has experienced a 0.36% rise in stock performance for the past week, with a 0.71% rise in the past month, and a 17.99% rise in the past quarter. The volatility ratio for the week is 8.90%, and the volatility levels for the past 30 days are at 6.24% for NUVB. The simple moving average for the past 20 days is 1.95% for NUVB’s stock, with a -1.75% simple moving average for the past 200 days.
Analysts’ Opinion of NUVB
Many brokerage firms have already submitted their reports for NUVB stocks, with Jefferies repeating the rating for NUVB by listing it as a “Buy.” The predicted price for NUVB in the upcoming period, according to Jefferies is $10 based on the research report published on March 27, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see NUVB reach a price target of $5. The rating they have provided for NUVB stocks is “Buy” according to the report published on March 26th, 2024.
Jefferies gave a rating of “Hold” to NUVB, setting the target price at $2 in the report published on January 06th of the previous year.
NUVB Trading at 7.25% from the 50-Day Moving Average
After a stumble in the market that brought NUVB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.21% of loss for the given period.
Volatility was left at 6.24%, however, over the last 30 days, the volatility rate increased by 8.90%, as shares sank -2.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.61% upper at present.
During the last 5 trading sessions, NUVB rose by +0.36%, which changed the moving average for the period of 200-days by +17.99% in comparison to the 20-day moving average, which settled at $2.77. In addition, Nuvation Bio Inc saw 86.75% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NUVB starting from Wang Junyuan Jerry, who sale 56,361 shares at the price of $2.89 back on Nov 11 ’24. After this action, Wang Junyuan Jerry now owns 3,866,228 shares of Nuvation Bio Inc, valued at $162,883 using the latest closing price.
Mashal Robert, the Director of Nuvation Bio Inc, purchase 100,000 shares at $2.20 during a trade that took place back on Oct 08 ’24, which means that Mashal Robert is holding 100,000 shares at $220,000 based on the most recent closing price.
Stock Fundamentals for NUVB
Current profitability levels for the company are sitting at:
- -55.42 for the present operating margin
- -0.33 for the gross margin
The net margin for Nuvation Bio Inc stands at -219.41. The total capital return value is set at -0.26. Equity return is now at value -95.54, with -88.53 for asset returns.
Based on Nuvation Bio Inc (NUVB), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -9.71. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -26.64.
Currently, EBITDA for the company is -99.6 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 383.46. The receivables turnover for the company is 0.57for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.57.
Conclusion
In conclusion, Nuvation Bio Inc (NUVB) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
